-
Posted: April 15th, 2024, 11:00pm UTC
Conditions: Prostate Cancer; Pathology
Interventions: Procedure: Transperineal Prostate Biopsy
Sponsors: West China Hospital
Not yet recruiting
-
Posted: December 7th, 2023, 1:00am UTC
Conditions: Pancreas Adenocarcinoma; Small-cell Lung Cancer; Glioblastoma, IDH-wildtype
Interventions: Genetic: Long term survival multimodal analysis
Sponsors: Cure 51; Gustave Roussy, Cancer Campus, Grand Paris; Centre Leon Berard; Vall d'Hebron Institute of Oncology; Istituto Europeo di Oncologia; Charite University, Berlin, Germany
Recruiting
-
Posted: November 3rd, 2023, 11:00pm UTC
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
-
Posted: April 26th, 2023, 11:00pm UTC
Conditions: Lung Adenocarcinoma, Stage I
Interventions: Diagnostic Test: Invasiveness diagnosis
Sponsors: Wuhan Union Hospital, China
Recruiting
-
Posted: March 18th, 2022, 11:00pm UTC
Conditions:
Pancreatic
Acinar
Cell
Carcinoma
Interventions:
Drug:
Olaparib
Sponsors:
National
Cancer
Institute
(NCI)
Active,
not
recruiting
-
Posted: August 2nd, 2021, 11:00pm UTC
Conditions: Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusion; CRAF Gene Fusion; CRAF Fusion; RAF1 Gene Fusion; RAF1 Fusion; Thyroid Cancer, Papillary; Spitzoid Melanoma; Pilocytic Astrocytoma; Pilocytic Astrocytoma, Adult; Non Small Cell Lung Cancer; Non-Small Cell Adenocarcinoma; Colorectal Cancer; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; Bladder Cancer; Bladder Urothelial Carcinoma; MAP Kinase Family Gene Mutation; RAS Mutation; RAF Mutation; MEK Mutation
Interventions: Drug: Tovorafenib; Drug: Pimasertib
Sponsors: Day One Biopharmaceuticals, Inc.
Active, not recruiting
-
Posted: April 26th, 2021, 11:00pm UTC
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Olaparib; Drug: Placebo Administration
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 31st, 2020, 1:00am UTC
Conditions:
Prostatic
Neoplasms,
Castration-Resistant;
Neoplasms
by
Histologic
Type;
Neoplasms,
Prostate;
Prostate
Cancer;
Metastatic
Castration-resistant
Prostate
Cancer;
Neoplasms;
Prostatic
Neoplasms;
Genital
Neoplasms,
Male;
Urogenital
Neoplasms;
Neoplasms
by
Site;
Prostatic
Disease;
Salivary
Gland
Cancer;
Salivary
Gland
Tumor;
Adenoid
Cystic
Carcinoma;
Salivary
Duct
Carcinoma;
Mucoepidermoid
Carcinoma;
Acinic
Cell
Tumor
Interventions:
Biological:
P-PSMA-101
CAR-T
cells;
Drug:
Rimiducid
Sponsors:
Poseida
Therapeutics,
Inc.
Terminated
-
Posted: November 4th, 2019, 1:00am UTC
Conditions: Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation
Interventions: Drug: Melphalan; Drug: BCNU; Drug: Vitamin B12B; Drug: Vitamin C; Drug: Ethanol; Device: Autologous Hematopoietic Stem Cells
Sponsors: General Oncology, Inc.; Myriad Genetics, Inc.
Recruiting
-
Posted: November 14th, 2018, 1:00am UTC
Conditions: Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: July 15th, 2016, 11:00pm UTC
Conditions:
Acinar
Cell
Carcinoma;
Adenoid
Cystic
Carcinoma;
Adrenal
Cortical
Carcinoma;
Adrenal
Gland
Pheochromocytoma;
Anal
Canal
Neuroendocrine
Carcinoma;
Anal
Canal
Undifferentiated
Carcinoma;
Angiosarcoma;
Apocrine
Neoplasm;
Appendix
Mucinous
Adenocarcinoma;
Bartholin
Gland
Transitional
Cell
Carcinoma;
Basal
Cell
Carcinoma;
Bladder
Adenocarcinoma;
Breast
Metaplastic
Carcinoma;
Cervical
Adenocarcinoma;
Cholangiocarcinoma;
Chordoma;
Colorectal
Squamous
Cell
Carcinoma;
Desmoid
Fibromatosis;
Endometrial
Transitional
Cell
Carcinoma;
Endometrioid
Adenocarcinoma;
Esophageal
Neuroendocrine
Carcinoma;
Esophageal
Undifferentiated
Carcinoma;
Extrahepatic
Bile
Duct
Carcinoma;
Extramammary
Paget
Disease;
Fallopian
Tube
Adenocarcinoma;
Fallopian
Tube
Transitional
Cell
Carcinoma;
Fibromyxoid
Tumor;
Gallbladder
Carcinoma;
Gastric
Neuroendocrine
Carcinoma;
Gastric
Squamous
Cell
Carcinoma;
Gastric
Undifferentiated
Carcinoma;
Gastrointestinal
Stromal
Tumor;
Gestational
Trophoblastic
Tumor;
Giant
Cell
Carcinoma;
Human
Papillomavirus-Independent
Cervical
Adenocarcinoma,
Clear
Cell-Type;
Intestinal
Neuroendocrine
Carcinoma;
Intrahepatic
Cholangiocarcinoma;
Lung
Neuroendocrine
Tumor;
Lung
Sarcomatoid
Carcinoma;
Major
Salivary
Gland
Carcinoma;
Malignant
Neoplasm
of
Unknown
Primary;
Malignant
Odontogenic
Neoplasm;
Malignant
Peripheral
Nerve
Sheath
Tumor;
Malignant
Solid
Neoplasm;
Malignant
Testicular
Sex
Cord-Stromal
Tumor;
Metastatic
Pituitary
Neuroendocrine
Tumor;
Minimally
Invasive
Lung
Adenocarcinoma;
Mixed
Mesodermal
(Mullerian)
Tumor;
Mucinous
Adenocarcinoma;
Mucinous
Cystadenocarcinoma;
Nasal
Cavity
Adenocarcinoma;
Nasal
Cavity
Carcinoma;
Nasopharyngeal
Carcinoma;
Nasopharyngeal
Low
Grade
Papillary
Adenocarcinoma;
Nasopharyngeal
Undifferentiated
Carcinoma;
Oral
Cavity
Carcinoma;
Oropharyngeal
Undifferentiated
Carcinoma;
Ovarian
Adenocarcinoma;
Ovarian
Germ
Cell
Tumor;
Ovarian
Mucinous
Adenocarcinoma;
Ovarian
Squamous
Cell
Carcinoma;
Ovarian
Transitional
Cell
Carcinoma;
Pancreatic
Acinar
Cell
Carcinoma;
Pancreatic
Neuroendocrine
Carcinoma;
Paraganglioma;
Paranasal
Sinus
Adenocarcinoma;
Paranasal
Sinus
Carcinoma;
Parathyroid
Gland
Carcinoma;
PEComa;
Penile
Squamous
Cell
Carcinoma;
Peritoneal
Mesothelial
Neoplasm;
Placental
Choriocarcinoma;
Primary
Peritoneal
High
Grade
Serous
Adenocarcinoma;
Pseudomyxoma
Peritonei;
Rare
Disorder;
Scrotal
Squamous
Cell
Carcinoma;
Seminal
Vesicle
Adenocarcinoma;
Seminoma;
Serous
Cystadenocarcinoma;
Small
Intestinal
Adenocarcinoma;
Small
Intestinal
Squamous
Cell
Carcinoma;
Spindle
Cell
Neoplasm;
Teratoma
With
Somatic-Type
Malignancy;
Testicular
Non-Seminomatous
Germ
Cell
Tumor;
Thyroid
Gland
Carcinoma;
Tracheal
Carcinoma;
Transitional
Cell
Carcinoma;
Ureter
Adenocarcinoma;
Ureter
Squamous
Cell
Carcinoma;
Urethral
Adenocarcinoma;
Urethral
Squamous
Cell
Carcinoma;
Vaginal
Adenocarcinoma;
Vaginal
Squamous
Cell
Carcinoma,
Not
Otherwise
Specified;
Vulvar
Carcinoma
Interventions:
Procedure:
Biospecimen
Collection;
Procedure:
Computed
Tomography;
Procedure:
Echocardiography
Test;
Biological:
Ipilimumab;
Procedure:
Magnetic
Resonance
Imaging;
Biological:
Nivolumab
Sponsors:
National
Cancer
Institute
(NCI)
Active,
not
recruiting
-
Posted: May 2nd, 2016, 11:00pm UTC
Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm; Periampullary Adenocarcinoma
Interventions: Procedure: Pancreatectomy; Other: Lavage; Procedure: Pancreatectomy; Other: Lavage; Procedure: Pancreatectomy
Sponsors: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting
-
Posted: April 8th, 2009, 11:00pm UTC
Conditions: Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Other: Diagnostic Laboratory Biomarker Analysis; Drug: Erlotinib Hydrochloride; Drug: Gemcitabine Hydrochloride; Drug: Vismodegib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: April 30th, 2008, 11:00pm UTC
Conditions: Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Biological: Falimarev; Biological: Inalimarev; Other: Laboratory Biomarker Analysis; Biological: Sargramostim
Sponsors: National Cancer Institute (NCI)
Active, not recruiting